KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Net Cash Flow: 2017-2025

Historic Net Cash Flow for Amneal Pharmaceuticals (AMRX) over the last 8 years, with Sep 2025 value amounting to $155.4 million.

  • Amneal Pharmaceuticals' Net Cash Flow rose 441.26% to $155.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $162.3 million, marking a year-over-year increase of 1043.23%. This contributed to the annual value of $20.3 million for FY2024, which is 68.17% down from last year.
  • As of Q3 2025, Amneal Pharmaceuticals' Net Cash Flow stood at $155.4 million, which was up 897.30% from $15.6 million recorded in Q2 2025.
  • Amneal Pharmaceuticals' Net Cash Flow's 5-year high stood at $155.4 million during Q3 2025, with a 5-year trough of -$172.9 million in Q2 2021.
  • Moreover, its 3-year median value for Net Cash Flow was $3.3 million (2023), whereas its average is $18.7 million.
  • As far as peak fluctuations go, Amneal Pharmaceuticals' Net Cash Flow slumped by 885.96% in 2023, and later spiked by 1,137.19% in 2024.
  • Amneal Pharmaceuticals' Net Cash Flow (Quarterly) stood at -$54.1 million in 2021, then dropped by 5.30% to -$56.9 million in 2022, then skyrocketed by 105.80% to $3.3 million in 2023, then surged by 1,137.19% to $40.8 million in 2024, then spiked by 441.26% to $155.4 million in 2025.
  • Its Net Cash Flow was $155.4 million in Q3 2025, compared to $15.6 million in Q2 2025 and -$49.6 million in Q1 2025.